Abstract
Transcatheter aortic valve implantation (TAVI) was developed as a therapeutic option for those patients who are deemed to be at high risk for surgical aortic valve replacement or inoperable. After the first case was performed by Professor Cribier from the Department of Cardiology, Rouen University in France in 2002 [Cribier A, Eltchaninoff H, Bash A, Borenstein N, Tron C, Bauer F, et al. Percutaneous transcatheter implantation of an aortic valve prosthesis for calcific aortic stenosis: first human case description. Circulation. 2002;106:3006–8], this therapeutic option received the CE Mark in Europe in 2007, and approval from the U.S. FDA was granted to the SAPIEN valve from Edward Lifesciences in 2011 and the CoreValve from Medtronic in 2014. Presently, over 150,000 patients have been treated with this technique worldwide, and it is rapidly improving and prevailing around the world. In October 2013, it finally received insurance reimbursement in Japan. Since then, over 8000 patients have been treated, and the number of facilities approved to perform the procedure is increasing.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Cribier A, Eltchaninoff H, Bash A, Borenstein N, Tron C, Bauer F, et al. Percutaneous transcatheter implantation of an aortic valve prosthesis for calcific aortic stenosis: first human case description. Circulation. 2002;106:3006–8.
Dvir D, Webb JG, Bleiziffer S, Pasic M, Waksman R, Kodali S, Valve-in-Valve International Data Registry Investigators, et al. Transcatheter aortic valve implantation in failed bioprosthetic surgical valves. JAMA. 2014;312:162–70.
Webb JG, Mack MJ, White JM, Dvir D, Blanke P, Herrmann HC, et al. Transcatheter aortic valve implantation within degenerated aortic surgical bioprostheses: PARTNER 2 valve-in-valve registry. J Am Coll Cardiol. 2017;69:2253–62.
Deeb GM, Chetcuti SJ, Reardon MJ, Patel HJ, Grossman PM, Schreiber T, et al. 1-year results in patients undergoing transcatheter aortic valve replacement with failed surgical bioprostheses. JACC Cardiovasc Interv. 2017;10:1034–44.
Roy DA, Schaefer U, Guetta V, Hildick-Smith D, Möllmann H, Dumonteil N, et al. Transcatheter aortic valve implantation for pure severe native aortic valve regurgitation. J Am Coll Cardiol. 2013;61:1577–84.
Taramasso M, Pozzoli A, Latib A, La Canna G, Colombo A, Maisano F, et al. New devices for TAVI: technologies and initial clinical experiences. Nat Rev Cardiol. 2014;11:157–67.
Franzone A, Piccolo R, Siontis GC, Lanz J, Stortecky S, Praz F, et al. Transcatheter aortic valve replacement for the treatment of pure native aortic valve regurgitation: a systematic review. JACC Cardiovasc Interv. 2016;9:2308–17.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2019 Springer Nature Singapore Pte Ltd.
About this chapter
Cite this chapter
Hayashida, K. (2019). ONE-POINT ADVICE: Significance of Aortic Valvuloplasty in the Valve-in-Valve Era. In: Kunihara, T., Takanashi, S. (eds) Aortic Valve Preservation. Springer, Singapore. https://doi.org/10.1007/978-981-13-2068-2_8
Download citation
DOI: https://doi.org/10.1007/978-981-13-2068-2_8
Published:
Publisher Name: Springer, Singapore
Print ISBN: 978-981-13-2067-5
Online ISBN: 978-981-13-2068-2
eBook Packages: MedicineMedicine (R0)